Martinsried, Germany – November 26, 2024 – Eisbach Bio GmbH, a pioneering precision oncology company, is pleased to announce the receipt of a Texas Therapeutics Company Award from the Cancer Prevention and Research Institute of Texas (CPRIT). This prestigious grant of US$4.75 million will support the clinical development of Eisbach’s first-in-class allosteric small molecule inhibitor EIS-12656 targeting ALC1, a chromatin remodeling enzyme and helicase that represents the mo

MARTINSRIED, Germany, September 16, 2024 – Eisbach Bio GmbH (“Eisbach” or the “Company”), a privately-held clinical-stage biotechnology company pioneering cancer medicines leveraging synthetic lethality, today announced that the first patient has been dosed in Module 1 of the ongoing Phase 1/2 MATCH clinical trial (NCT06525298) investigating the small molecule ALC1 inhibitor EIS-12656 in solid tumors. In this trial, Eisbach seeks to assess the safety, pharmacokinetics, pharm

Munich, 18.07.2024 : Eisbach Bio GmbH is set to train the next generation of scientists in the metabolic regulation of genome function through the innovative project NUCLEAR. Coordinated by the Josep Carreras Leukaemia Research Institute near Barcelona, Spain, this network will guide 17 doctoral candidates to become world-class experts and provide new insights at the interface of metabolism and genome regulation, a topic highly relevant to stem cell biology, obesity and cance

MARTINSRIED, Germany, May 24, 2024 – Eisbach Bio GmbH (“Eisbach” or the “Company”), a privately-held clinical-stage biotechnology company pioneering cancer medicines leveraging synthetic lethality, has announced completion and Phase I topline results of EIS-10700. The safety, tolerability and pharmacokinetics of EIS-10700 were investigated in a first-in-human, open label, single center, single dose escalation Phase I study in Germany. Due to the excellent safety profile obta

MARTINSRIED, Germany, May 6, 2024 – Eisbach Bio GmbH (“Eisbach” or the “Company”), a privately-held clinical-stage biotechnology company pioneering cancer medicines leveraging synthetic lethality, has announced United States Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application for EIS-12656, a small molecule inhibiting the chromatin helicase ALC1 (CHD1L). EIS-12656 targets ALC1 through allosteric mechanisms, suppressing the cancer-re

MARTINSRIED, Germany and HOUSTON, Texas, March 21, 2024 –  Eisbach Bio GmbH (Eisbach), a clinical-stage biotechnology company pioneering a new class of cancer medicines leveraging synthetic lethality to target specific proteins that are essential for the survival of cancer cells, and Cancer Focus Fund, LP , a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) to provide funding and clinical expertise to a

Munich, 26.04.2023 : Eisbach Bio GmbH, a biotechnology company targeting the molecular machines that drive human disease, today announced the start of a Phase 1, first-in-human clinical trial for EIS-10700, a small molecule that targets the RNA helicase of SARS-CoV-2. Eisbach Bio is developing a COVID-19 antiviral as part of the EisCor2 project supported by the German Federal Ministry of Research (BMBF). The trial is designed to evaluate the safety, tolerability, and pharmaco

A nucleic acid chemistry cluster to shape Germany’s R&D future – Eisbach member of the winning C-NATM cluster   Munich, 08.08.2022 : The cluster C-NATM has emerged as one of the 7 winners in the Clusters4Future competition funded by the German Federal Ministry of Education and Research (BMBF). Eisbach Bio GmbH will contribute its proprietary R&D expertise to the network and develop novel nucleic acid-based therapies for oncology. The C-NATM network led by Prof. Dr. Thomas Car

Eisbach Bio and MD Anderson announce strategic collaboration to develop medicines targeting epigenetic machinery in oncology MUNICH and HOUSTON ― Eisbach Bio GmbH and The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution. The agreement aligns the drug discovery and development expertise of MD Anderson’s Th

MUNICH, Germany. April 16 th , 2021 – Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease today announced additional financial support from the German Ministry for Education and Research (BMBF) for the clinical development of its first-in-class SARS-CoV-2 helicase inhibitor. Leveraging Eisbach’s proprietary drug discovery platform, the company has concluded preclinical development of its candidate molecule. Eisbach and 7 additional

MUNICH, Germany, October 29, 2021 – Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease, announces financial support from the Bavarian Ministry of Economic Affairs, Regional Development and Energy (StMWi) for the preclinical and clinical development of a proprietary SARS-CoV-2 helicase inhibitor and its backups. The funding of EUR 6.7 million will support the development of the Company’s COVID-19 therapeutics and maintain the compet

MUNICH, Germany, September 1, 2021 –  Eisbach Bio GmbH and the team of Prof. Dr.-Ing. Naim Bajcinca from the Technische Universität Kaiserlautern (TUK) announce a collaboration where they will use deep learning to track and trace arising mutations in the genome of SARS-CoV-2 and develop sustainable small molecule inhibitors that will target the virus for the long-term. The project titled AI-based Mutation Prediction and Relevant Protein Inhibitor Development in SARS-CoV-2 (AI

MUNICH, Germany, July 7, 2021 – Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease, today announced additional financial support from the German Ministry for Education and Research (BMBF) for the clinical development of its first-in-class SARS-CoV-2 helicase inhibitor. The total funding of EUR 8 million will support the clinical development of the Company’s novel COVID-19 therapeutic following the recent completion of its preclinic

The Core Facility Animal Models (CAM) of the Biomedical Center of the LMU announces a collaboration with drug discovery start-up Eisbach Bio GmbH to test SARS-CoV-2 antivirals. Eisbach has developed small molecule inhibitors which target disease-relevant and novel mechanisms in SARS-CoV-2 for the treatment of COVID-19 and is now concluding late-stage pre-clinical development together with the CAM. The CAM is conducting animal studies to evaluate the new compounds with respe